Labcorp buys BioReference lab businesses in $872M deal
Labcorp will acquire selected BioReference assets for $722 million cash plus up to $150 million earnout, adding clinical, women’s health, urology and correctional testing and more than 80 service centers.
16 Oct 2026 0 reads Compiled with AI
#Labcorp #BioReference #Opko #4Kscore #FDA
The acquisition covers clinical and women’s health testing services, urology, corrections testing and operational assets, including more than 80 patient service centers that will expand Labcorp’s reach. Evercore ISI analysts said the new business could generate about $250 million in revenue in its first year after closing.
Deal structure and scope
The deal also secures BioReference’s FDA‑approved 4Kscore blood test, which predicts the likelihood of aggressive prostate cancer and can help avoid unnecessary biopsies. The test has been available as a laboratory‑developed test since 2014 and received FDA approval in 2021. Opko plans to use the transaction to streamline its operations and focus more resources on its biopharmaceutical business while Labcorp expands national access to the test and other specialty diagnostics.
The transaction is subject to regulatory approval and customary closing conditions. Until the deal closes, both companies will continue to operate independently with no changes to their current services or operations. The acquisition aligns with Labcorp’s strategy of expanding in high‑growth specialty testing and is expected to enhance revenue and service access across the United States.